{
    "id": "b66d4732-da1d-4624-93bf-6edaa303566b",
    "indications": "leflunomide pyrimidine synthesis inhibitor indicated treatment adults active rheumatoid arthritis . ( 1 )",
    "contraindications": "loading patients low risk leflunomide tablets -associated hepatotoxicity leflunomide tablets-associated myelosuppression : 100 mg daily 3 days . ( 2.1 ) maintenance : 20 mg daily . ( 2.1 ) maximum recommended daily : 20 mg daily . ( 2.1 ) 20 mg daily tolerated , may decrease 10 mg daily . ( 2.1 ) screen patients active latent tuberculosis , pregnancy test ( females ) , blood pressure , laboratory tests starting leflunomide tablets . ( 2.2 )",
    "warningsAndPrecautions": "supplied leflunomide tablets , usp ; 10 mg 20 mg strength quantity ndc number description 10 mg 30 count bottle 70748-129-06 white off-white , round film coated tablet , free physical defects , debossed `` l `` one side `` a4 `` side . 20 mg 30 count bottle 70748-130-06 yellow colour , film coated , round shaped tablet , free physical defects , debossed `` l `` one side `` a5 `` side . store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . protect light .",
    "adverseReactions": "leflunomide tablet contraindicated : pregnant women . leflunomide tablets may cause fetal harm . woman becomes pregnant taking , stop leflunomide tablets , apprise patient potential hazard fetus , begin elimination procedure [ ( 5.1 , 5.3 ) ( 8.1 ) ] . patients severe hepatic impairment [ ( 5.2 ) ] . patients known hypersensitivity leflunomide components leflunomide tablets . known include anaphylaxis [ ( 6.1 ) ] . patients treated teriflunomide [ ( 7 ) ] .",
    "ingredients": [
        {
            "name": "LEFLUNOMIDE",
            "code": "G162GK9U4W"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "organization": "Lupin Pharmaceuticals, Inc.",
    "name": "Leflunomide",
    "effectiveTime": "20250514",
    "indications_original": "Leflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of adults with active rheumatoid arthritis. ( 1 )",
    "contraindications_original": "Loading dosage for patients at low risk for      leflunomide tablets -associated hepatotoxicity and leflunomide      tablets-associated myelosuppression: 100 mg daily for 3 days. ( 2.1 ) Maintenance dosage: 20 mg daily. ( 2.1 ) Maximum recommended      daily dosage: 20 mg once daily. ( 2.1 ) If 20 mg once daily is      not tolerated, may decrease dosage to 10 mg once daily. ( 2.1 ) Screen patients for active and latent      tuberculosis, pregnancy test (females), blood pressure, and laboratory      tests before starting leflunomide tablets. ( 2.2 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  \n                     Leflunomide Tablets, USP; 10 mg and 20 mg\n                  \n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                               Strength\n                              \n                           \n                           \n                               Quantity\n                              \n                           \n                           \n                               NDC Number\n                              \n                           \n                           \n                               Description\n                              \n                           \n                        \n                        \n                            10 mg\n                           \n                            30 count bottle\n                           \n                            70748-129-06\n                           \n                            White to off-white, round film coated tablet, free from physical defects, debossed with \"L\" on one side and \"A4\" on the other side.\n                           \n                        \n                        \n                            20 mg\n                           \n                            30 count bottle\n                           \n                            70748-130-06\n                           \n                            Yellow colour, film coated, round shaped tablet, free from physical defects, debossed with \"L\" on one side and \"A5\" on the other side.\n                           \n                        \n                     \n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light.",
    "adverseReactions_original": "Leflunomide tablet is contraindicated in:\n                  \n                     Pregnant women. Leflunomide tablets may cause fetal harm.  If a woman becomes pregnant while taking this drug, stop leflunomide tablets, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see Warnings and Precautions (5.1 , 5.3) and Use in Specific Populations (8.1)].\n                     \n                     Patients with severe hepatic impairment [see Warnings and Precautions (5.2)].\n                     \n                     Patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. Known reactions include anaphylaxis [see Adverse Reactions (6.1)].\n                     \n                     Patients being treated with teriflunomide [see Drug Interactions (7)]."
}